Eczema

Melinda Gooderham, MSc, MD, FRCPC, provided insights into the significance of the DELTA 3 extension data presented at AAD 2024.

In a recent study, topical ruxolitinib improved clinical outcomes, itch, and patient quality of life.

Patients treated with the ointment showed improvement in lesional percentage body surface area.

Both cream options were capable of reducing scores of itching, drying, burning, redness, and more.

Dermatologists Jeanine Downie, DiAnne Davis, and Hope Mitchell reveal the La Roche-Posay products they recommend to patients with dry skin, eczema, and more, at the flagship store in France.

An OTC moisturizer was found to improve skin ceramide levels in patients with eczema-prone skin.

Zoryve was approved for the treatment of seborrheic dermatitis in patients ages 9 years and older in December.

In a recent study, prenatal opioid exposure was also linked to increased odds of infections and asthma, but not with allergies, anaphylaxis, orautoimmune conditions.

Data from Arcutis’ STRATUM study was presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

Ten posters at the Winter Clinical Hawaii and Maui Derm Conferences will showcase investigational data to expand treatment options for patients with atopic dermatitis and chronic hand eczema.